Arcutis Biotherapeutics (ARQT) Operating Leases (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Operating Leases of $5.3 million for Q1 2026, up 124.4% year-over-year from $2.3 million in Q1 2025, and little changed quarter-over-quarter from $5.3 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Operating Leases (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $5.3 million for Q1 2026.
- In Q1 2026, Operating Leases rose 124.4% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (up 124.4% YoY), while the FY2025 annual figure was $5.3 million, up 105.54% from the prior year.
- Operating Leases for Q1 2026 stood at $5.3 million, roughly flat from $5.3 million in the prior quarter.
- The five-year high for Operating Leases was $5.3 million in Q3 2025, with the low at $2.1 million in Q2 2025.
- The 5-year median for Operating Leases is $3.9 million (2023), against an average of $3.9 million.
- The sharpest annual moves came in 2024 and 2026: Operating Leases sank 33.08% in 2024, then soared 124.4% in 2026.
- Arcutis Biotherapeutics' Operating Leases stood at $4.1 million in 2022, then decreased by 17.85% to $3.4 million in 2023, then fell by 24.25% to $2.6 million in 2024, then soared by 105.54% to $5.3 million in 2025, then decreased by 0.28% to $5.3 million in 2026.
- Business Quant data shows ARQT's Operating Leases at $5.3 million in Q1 2026, $5.3 million in Q4 2025, and $5.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.24 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | 5.27 Mn |
| Sep 30, 2025 | 5.28 Mn |
| Jun 30, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 2.56 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 2.98 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 3.38 Mn |
| Sep 30, 2023 | 3.57 Mn |
| Jun 30, 2023 | 4.45 Mn |
| Mar 31, 2023 | 3.94 Mn |
| Dec 31, 2022 | 4.12 Mn |
| Sep 30, 2022 | 4.92 Mn |
| Jun 30, 2022 | 4.45 Mn |
| Mar 31, 2022 | 5.12 Mn |
| Dec 31, 2021 | 4.77 Mn |
| Sep 30, 2021 | 4.92 Mn |